324 related articles for article (PubMed ID: 25398834)
41. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Giannopoulos K; Mertens D; Stilgenbauer S
Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
[TBL] [Abstract][Full Text] [Related]
42. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.
Giannopoulos K; Dmoszynska A; Kowal M; Wasik-Szczepanek E; Bojarska-Junak A; Rolinski J; Döhner H; Stilgenbauer S; Bullinger L
Leukemia; 2009 Oct; 23(10):1771-8. PubMed ID: 19440214
[TBL] [Abstract][Full Text] [Related]
43. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
Molica S
Leuk Lymphoma; 2007 May; 48(5):866-9. PubMed ID: 17487728
[TBL] [Abstract][Full Text] [Related]
44. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Gassner FJ; Zaborsky N; Neureiter D; Huemer M; Melchardt T; Egle A; Rebhandl S; Catakovic K; Hartmann TN; Greil R; Geisberger R
Haematologica; 2014 May; 99(5):67-9. PubMed ID: 24561794
[No Abstract] [Full Text] [Related]
45. Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
Lafarge ST; Johnston JB; Gibson SB; Marshall AJ
Leuk Res; 2014 Jan; 38(1):109-15. PubMed ID: 23981382
[TBL] [Abstract][Full Text] [Related]
46. Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia.
Ysebaert L; Fournié JJ
Leuk Lymphoma; 2011 Jul; 52(7):1404-6. PubMed ID: 21699388
[TBL] [Abstract][Full Text] [Related]
47. Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2.
Schulz A; Toedt G; Zenz T; Stilgenbauer S; Lichter P; Seiffert M
Haematologica; 2011 Mar; 96(3):408-16. PubMed ID: 21134984
[TBL] [Abstract][Full Text] [Related]
48. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Srinivasan S; Schiffer CA
Leuk Res; 2009 Apr; 33(4):561-4. PubMed ID: 18676017
[TBL] [Abstract][Full Text] [Related]
49. Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia.
Kriston C; Hernádfői M; Plander M; Márk Á; Takács F; Czeti Á; Szalóki G; Szabó O; Matolcsy A; Barna G
Hematol Oncol; 2021 Oct; 39(4):513-520. PubMed ID: 34013974
[TBL] [Abstract][Full Text] [Related]
50. Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.
Ramsay AD; Rodriguez-Justo M
Br J Haematol; 2013 Jul; 162(1):15-24. PubMed ID: 23617880
[TBL] [Abstract][Full Text] [Related]
51. Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.
van Attekum MH; Eldering E; Kater AP
Haematologica; 2017 Sep; 102(9):1469-1476. PubMed ID: 28775118
[TBL] [Abstract][Full Text] [Related]
52. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
Spina F; Rezzonico F; Farina L; Corradini P
Eur J Haematol; 2013 Apr; 90(4):340-4. PubMed ID: 23281656
[TBL] [Abstract][Full Text] [Related]
53. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
Masood A; Chitta K; Paulus A; Khan AN; Sher T; Ersing N; Miller KC; Manfredi D; Ailawadhi S; Borrelo I; Lee KP; Chanan-Khan A
Br J Haematol; 2012 Apr; 157(1):59-66. PubMed ID: 22171982
[TBL] [Abstract][Full Text] [Related]
54. Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.
Hanna BS; McClanahan F; Yazdanparast H; Zaborsky N; Kalter V; Rößner PM; Benner A; Dürr C; Egle A; Gribben JG; Lichter P; Seiffert M
Leukemia; 2016 Mar; 30(3):570-9. PubMed ID: 26522085
[TBL] [Abstract][Full Text] [Related]
55. Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis.
Palmieri EM; Menga A; Martín-Pérez R; Quinto A; Riera-Domingo C; De Tullio G; Hooper DC; Lamers WH; Ghesquière B; McVicar DW; Guarini A; Mazzone M; Castegna A
Cell Rep; 2017 Aug; 20(7):1654-1666. PubMed ID: 28813676
[TBL] [Abstract][Full Text] [Related]
56. B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia.
Galletti G; Caligaris-Cappio F; Bertilaccio MT
Leukemia; 2016 Dec; 30(12):2293-2301. PubMed ID: 27677742
[TBL] [Abstract][Full Text] [Related]
57. Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?
Asslaber D; Grössinger EM; Girbl T; Hofbauer SW; Egle A; Weiss L; Greil R; Hartmann TN
Br J Haematol; 2013 Mar; 160(5):711-4. PubMed ID: 23205585
[No Abstract] [Full Text] [Related]
58. CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis.
van Attekum MHA; van Bruggen JAC; Slinger E; Lebre MC; Reinen E; Kersting S; Eldering E; Kater AP
Haematologica; 2017 Dec; 102(12):2069-2076. PubMed ID: 28971904
[TBL] [Abstract][Full Text] [Related]
59. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
Herman SE; Lapalombella R; Gordon AL; Ramanunni A; Blum KA; Jones J; Zhang X; Lannutti BJ; Puri KD; Muthusamy N; Byrd JC; Johnson AJ
Blood; 2011 Apr; 117(16):4323-7. PubMed ID: 21378270
[TBL] [Abstract][Full Text] [Related]
60. Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
Arumainathan A; Kalakonda N; Pettitt AR
Eur J Haematol; 2011 Oct; 87(4):372-5. PubMed ID: 21679253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
